NCT03340376View on ClinicalTrials.gov

Doxorubicin Alone Versus Atezolizumab Alone Versus Doxorubicin and Atezolizumab in Recurrent Cervical Cancer

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

48

Participants

Timeline

Start Date

August 30, 2017

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2025

Conditions

Cervical Cancer

Interventions

DRUG

Atezolizumab

atezolizumab

DRUG

Doxorubicin

Doxorubicin

Trial Locations (1)

3000

UZLeuven, Leuven

All Listed Sponsors

collaborator

Roche Pharma AG

INDUSTRY

lead

Universitaire Ziekenhuizen KU Leuven

OTHER